Cortex Pharmaceuticals (RSPI) Stock Price, News & Analysis

Company Overview

Cortex Pharmaceuticals, Inc. (OTCMKTS: RSPI) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapeutics for the treatment of central nervous system disorders. The company’s proprietary platform centers on positive allosteric modulators of the AMPA receptor, commonly known as ampakines, which are designed to enhance synaptic transmission and support neuronal function in a variety of neurological conditions.

The company’s lead product candidates include CX717, CX1739 and CX1942, each of which is being evaluated for distinct indications such as opioid-induced respiratory depression, attention-deficit/hyperactivity disorder (ADHD) and cognitive impairment associated with aging or disease. Cortex has advanced these compounds through preclinical and early-stage clinical studies and has collaborated with pharmaceutical partners to explore broader therapeutic applications and formulation strategies.

Founded in 1996 and headquartered in Irvine, California, Cortex Pharmaceuticals operates a research facility staffed by scientists with deep expertise in neuropharmacology and drug development. The management team brings together years of experience in advancing investigational therapies from discovery through clinical proof-of-concept, with the goal of addressing unmet medical needs in neurology.

Cortex continues to refine its pipeline through strategic collaborations and internally driven research initiatives, seeking to translate its ampakine technology into safe and effective treatments that improve patient outcomes across multiple neurological indications.

Key Stats

• Today's Range: $0.0006 to $0.0006
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0027
• Volume: 60,100 shs
• Average Volume: 668,112 shs
• Market Capitalization: $569.68 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RSPI Stock Analysis - Frequently Asked Questions

How have RSPI shares performed this year?

Cortex Pharmaceuticals' stock was trading at $0.0008 at the beginning of the year. Since then, RSPI stock has decreased by 25.0% and is now trading at $0.0006.

How were Cortex Pharmaceuticals' earnings last quarter?

Cortex Pharmaceuticals Inc. (OTCMKTS:RSPI) posted its quarterly earnings results on Wednesday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of Cortex Pharmaceuticals?

Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cortex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cortex Pharmaceuticals investors own include American Bio Medica (ABMC), Galaxy Next Generation (GAXY), Asia Broadband (AABB), Aquestive Therapeutics (AQST), Appian (APPN), Arista Networks (ANET) and AMC Entertainment (AMC).

Company Calendar

• Last Earnings: 8/19/2020
• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RSPI
• CIK: 849636
• Web: www.respirerx.com
• Phone: (201) 444-4947
• Fax: 949-727-3657
• Employees: 2
• Year Founded: 1988

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 949,464,000
• Free Float: 474,447,000
• Market Cap: $569.68 thousand
• Optionable: Not Optionable
• Beta: 0.35